JP2023539125A5 - - Google Patents

Info

Publication number
JP2023539125A5
JP2023539125A5 JP2023512139A JP2023512139A JP2023539125A5 JP 2023539125 A5 JP2023539125 A5 JP 2023539125A5 JP 2023512139 A JP2023512139 A JP 2023512139A JP 2023512139 A JP2023512139 A JP 2023512139A JP 2023539125 A5 JP2023539125 A5 JP 2023539125A5
Authority
JP
Japan
Prior art keywords
disorders
disorder
compound according
exceeds
salt form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539125A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046935 external-priority patent/WO2022040545A1/en
Publication of JP2023539125A publication Critical patent/JP2023539125A/ja
Publication of JP2023539125A5 publication Critical patent/JP2023539125A5/ja
Pending legal-status Critical Current

Links

JP2023512139A 2020-08-20 2021-08-20 有機化合物 Pending JP2023539125A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068222P 2020-08-20 2020-08-20
US63/068,222 2020-08-20
PCT/US2021/046935 WO2022040545A1 (en) 2020-08-20 2021-08-20 Organic compounds

Publications (2)

Publication Number Publication Date
JP2023539125A JP2023539125A (ja) 2023-09-13
JP2023539125A5 true JP2023539125A5 (cg-RX-API-DMAC7.html) 2024-08-28

Family

ID=80350596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512139A Pending JP2023539125A (ja) 2020-08-20 2021-08-20 有機化合物

Country Status (4)

Country Link
US (1) US20230416300A1 (cg-RX-API-DMAC7.html)
EP (1) EP4200312A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023539125A (cg-RX-API-DMAC7.html)
WO (1) WO2022040545A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US12325726B2 (en) 2018-12-17 2025-06-10 Intra-Cellular Therapies, Inc. Organic compounds
CN117715641A (zh) * 2021-04-26 2024-03-15 普拉西斯精密医药公司 用神经活性类固醇进行治疗的方法
EP4650359A1 (en) * 2022-07-28 2025-11-19 Hunan Kyf Pharmaceutical. Co., Ltd. Steroid compound for treating central nervous system disease, method for preparing same, and use and pharmaceutical composition thereof
CN116606341B (zh) * 2022-07-28 2026-07-24 湖南科益新生物医药有限公司 治疗中枢神经系统疾病的甾体化合物及其制备方法、用途和药物组合物
WO2024059608A1 (en) * 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids
JP2026516023A (ja) * 2023-05-11 2026-05-19 シューチン バイオファーマ カンパニー リミテッド ステロイド系化合物、製造方法及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
DK1038880T3 (da) * 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
UA73736C2 (en) * 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
MY190408A (en) * 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
EP3229350B1 (en) * 2016-04-08 2021-06-23 Black & Decker Inc. Brushless motor for a power tool
US20200291059A1 (en) * 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CA3086299A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US12325726B2 (en) * 2018-12-17 2025-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid

Similar Documents

Publication Publication Date Title
JP2022513933A5 (cg-RX-API-DMAC7.html)
JP2021519267A5 (cg-RX-API-DMAC7.html)
JP2023527575A5 (cg-RX-API-DMAC7.html)
CN100455560C (zh) 含长链脂肪酰基取代的文拉法辛前体药物及其制备方法和用途
JP2022535093A (ja) 重水素化された又は部分的に重水素化されたn,n-ジメチルトリプタミン化合物を含む治療用組成物
JP2017531020A5 (cg-RX-API-DMAC7.html)
CN113423686B (zh) 氯胺酮双羟萘酸盐及其用途
RU2011119990A (ru) Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина
US5552418A (en) Trisubstituted Naphthylalkylamides
RU2012127770A (ru) Полициклические соединения и способы их применения
JP2009527462A5 (cg-RX-API-DMAC7.html)
JP2024531437A5 (cg-RX-API-DMAC7.html)
JP6130071B2 (ja) 1,7−ナフチリジン誘導体
JP2023509798A5 (cg-RX-API-DMAC7.html)
AU2011324414A1 (en) Trans-2-decenoic acid derivative and pharmaceutical agent containing the same
JP2025501411A5 (cg-RX-API-DMAC7.html)
CN113717133B (zh) 3-酰胺基-n-芳基苯甲酰胺类化合物及应用
RU2021119458A (ru) Органические соединения
CN1984878B (zh) 用于治疗神经变性疾病的1-苯基烷羧酸的衍生物
EP1596866A2 (en) Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
HUE024560T2 (hu) Pantenil-dokozahexanoát, valamint ennek alkalmazása szív-érrendszeri betegségek kezelésére és megelõzésére
CA3118954C (en) Ketamine pamoate and use thereof
BR112021013340B1 (pt) Sal de pamoato de cetamina e usos de uma composição farmacêutica compreendendo o referido sal
RU2024126638A (ru) Кристаллы производного витамина d или кристаллы его сольвата
RU2025117909A (ru) Соединение ингибитора пиридазина nlrp3, фармацевтическая композиция, способ его получения и его применение